Specialized pro-resolving mediator (SPM)-enriched supplementation modulates inflammatory biomarkers in patients with symptomatic knee osteoarthritis: Blood plasma analysis from the GAUDI study.
Prostaglandins Leukot Essent Fatty AcidsJun 10, 2026 (epub)
Clinical ResearchRheumatology
Ingrid Möller, Gil Rodas, Jose María Villalón et al.
✦ AI-curated · Sources linked
In 30 seconds
This secondary analysis of the GAUDI study, a randomized controlled trial, evaluated the effects of specialized pro-resolving mediator (SPM) supplementation on inflammatory biomarkers in adults with symptomatic knee osteoarthritis. The results indicated a tendency for reductions in IL-1 and IL-18 levels in the SPM group compared to placebo, with IL-1 changes correlating positively with improvements in WOMAC scores.
Key findings
- IL-1 levels decreased by 15.9 pg/ml in the SPM group compared to -1.1 pg/ml in placebo (p=0.051).
- IL-18 levels showed a change of 10.3 pg/ml in the SPM group versus -1.4 pg/ml in placebo (p=0.29).
- Changes in IL-1 and IL-8 positively correlated with improvements in WOMAC scores (r = 0.707, p=0.005).
- In patients with BMI ≥25 kg/m², most inflammatory biomarkers tended to decrease after SPM supplementation.
Why it matters
Understanding the role of SPMs in modulating inflammation could provide insights into new therapeutic strategies for managing knee osteoarthritis, a condition that significantly impacts patient quality of life and functional ability.